Back to resultsProstate Adenocarcinoma TransCutaneous Hormones (PATCH)
Primary Purpose
Anemia, Cardiovascular Complications, Hot Flashes
Status
Unknown status
Phase
Phase 3
Locations
United Kingdom
Study Type
Interventional
Intervention
Goserelin
Estradiol
Sponsored by
About this trial
This is an interventional treatment trial for Anemia focused on measuring hot flashes, anemia, osteoporosis, cardiovascular complications, recurrent prostate cancer, stage III prostate cancer, stage IV prostate cancer, adenocarcinoma of the prostate
Eligibility Criteria
DISEASE CHARACTERISTICS: Must meet 1 of the following criteria: Newly diagnosed patients with any of the following: Stage T3 or T4, NX, M0 histologically confirmed prostate adenocarcinoma with prostate-specific antigen (PSA) ≥ 20 ng/mL or Gleason score ≥ 6 Any T, N+, M0, or any T, any N, M+ histologically confirmed prostate adenocarcinoma Multiple sclerotic bone metastases with a PSA ≥ 50 ng/mL without histological confirmation Patients with histologically confirmed prostate adenocarcinoma previously treated with radical surgery or radiotherapy who are currently in relapse with on of the following: PSA ≥ 4 ng/mL and rising with doubling time less than 6 months PSA ≥ 20 ng/mL Must have written informed consent Intention to treat with long-term androgen-deprivation therapy Normal testosterone level prior to hormonal treatment PATIENT CHARACTERISTICS: WHO performance status 0-2 No other prior or current malignant disease or cardiovascular system disease that is likely to interfere with study treatment or assessment No cardiovascular disease, including any of the following: History of cerebral ischemia (e.g., stroke or transient ischemic attack) within the past 2 years History of deep vein thrombosis or pulmonary embolism confirmed radiologically History of myocardial infarction (MI) within the past 6 months OR MI more than 6 months ago with evidence of q-wave anterior infarct on ECG ECHO or MUGA required for patients with history of ischemic heart disease Left Ventricular Ejection Fraction ≤ 40% No condition or situation that could preclude protocol treatment or compliance with follow-up schedule PRIOR CONCURRENT THERAPY: See Disease Characteristics At least 12 months since prior adjuvant or neoadjuvant hormonal therapy for localized prostate cancer AND therapy lasted ≤ 12 months in duration No prior systemic therapy for locally advanced or metastatic prostate cancer No concurrent participation in another clinical trial of prostate cancer treatment that would preclude study therapy or outcome measures Concurrent prophylactic radiotherapy to prevent gynecomastia allowed
Sites / Locations
- Queen's HospitalRecruiting
- Addenbrooke's HospitalRecruiting
- Walsgrave HospitalRecruiting
- Mid Cheshire Hospitals Trust- Leighton HopsitalRecruiting
- Mayday University HospitalRecruiting
- Derbyshire Royal InfirmaryRecruiting
- Castle Hill HospitalRecruiting
- Royal Devon and Exeter HospitalRecruiting
- Grantham and District HospitalRecruiting
- Ipswich HospitalRecruiting
- Kidderminster HospitalRecruiting
- Leeds Cancer Centre at St. James's University HospitalRecruiting
- St. Mary's HospitalRecruiting
- Charing Cross HospitalRecruiting
- Maidstone HospitalRecruiting
- James Cook University HospitalRecruiting
- Kings Mill HospitalRecruiting
- Nottingham City HospitalRecruiting
- George Eliot HospitalRecruiting
- Alexandra Healthcare NHSRecruiting
- Hope HospitalRecruiting
- Scarborough General HospitalRecruiting
- Stepping Hill HospitalRecruiting
- Hillingdon HospitalRecruiting
- Walsall Manor HospitalRecruiting
- Warwick HospitalRecruiting
- Worthing HospitalRecruiting
- Yeovil District HospitalRecruiting
- Ayr HospitalRecruiting
- Beatson West of Scotland Cancer CentreRecruiting
- Velindre Cancer Center at Velindre HospitalRecruiting
- University Hospital of WalesRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
LHRH agonists
Oestrogen Patches
Arm Description
Patients randomised to the control arm will receive continuous treatment with LHRH agonists as per local practice. Treatment should continue for at least 3 years. LHRH antagonists, such as degarelix, are not allowed on the trial. The recommended "anti-flare" medication is bicalutamide and should be prescribed according to local practice. Control arm medication should be obtained from the hospital pharmacy or GP as per local practice.
Patients randomised to the investigational arm will receive transcutaneous oestrogen patches (100 micrograms/24 hours). Treatment should be planned to continue for at least 3 years. For patients prescribed bicalutamide or flutamide prior to randomisation, this treatment should be discontinued before treatment with the patches can commence (no washout period is needed).
Outcomes
Primary Outcome Measures
Progression-Free Survival
Overall Survival
Secondary Outcome Measures
Hormone activity by castrate levels of hormones
Other toxicity
Cardiovascular morbidity
Cardiovascular mortality
Quality of Life
will be measured using patient-completed questionnaires, EORTC QLQ-C30 and PR25 which is prostate specific
Full Information
NCT ID
NCT00303784
First Posted
March 15, 2006
Last Updated
November 24, 2020
Sponsor
University College, London
Collaborators
Medical Research Council
1. Study Identification
Unique Protocol Identification Number
NCT00303784
Brief Title
Prostate Adenocarcinoma TransCutaneous Hormones
Acronym
PATCH
Official Title
A Randomized-Controlled Trial of Transcutaneous Oestrogen Patches Versus LHRH Agonists in Prostate Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
March 2006 (Actual)
Primary Completion Date
August 2021 (Anticipated)
Study Completion Date
August 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University College, London
Collaborators
Medical Research Council
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
RATIONALE: The increasingly prolonged and extended use of androgen deprivation therapy (ADT) in the treatment of prostate cancer, usually achieved through the administration of LHRH agonists, has raised concerns about long-term toxicities, in particular osteoporosis and adverse metabolic changes which may be associated with type II diabetes and increased cardiovascular risk. An alternative approach is to investigate other methods of ADT. Oral oestrogen has been shown to be as effective as LHRH and surgical orchidectomy in achieving castrate levels of testosterone and has equivalent or improved prostate cancer outcomes but is not used routinely as first-line therapy because of the risk of cardiovascular system (CVS) complications. The CVS complications have been attributed to first-pass hepatic metabolism. Administering oestrogen parenterally avoids the entero-hepatic circulation and so is expected to mitigate the risk of CVS toxicity whilst still effectively suppressing testosterone to castrate levels. This hypothesis has been supported by results from the early stages of this trial which have provided sufficient indication of the safety and efficacy of the patches to warrant further investigation of the treatment in this setting, as recommended by the IDMC..
PURPOSE: This randomized phase III trial is studying how well the estrogen skin patch works compared with luteinizing hormone-releasing hormone agonist injections in treating patients with locally advanced or metastatic prostate cancer.
Detailed Description
OBJECTIVES:
Primary
Compare the progression-free survival and overall survival of patients with locally advanced or metastatic prostate cancer treated with transcutaneous estrogen patches vs luteinizing hormone-releasing hormone analogues.
Secondary
Compare the cardiovascular system-related morbidity and mortality in patients treated with these regimens
Compare the activity of these treatments, in terms of castrate level of hormones, failure-free survival, and biochemical failure, in these patients.
Compare other toxicities, including osteoporosis, hot flushes, gynecomastia, and anemia, in patients treated with these regimens.
Compare the quality of life of patients treated with these regimens.
OUTLINE: This is a randomized, controlled, multicenter study. Patients are randomized to 1 of 2 treatment arms at 1(control):1 (patch) ratio.
Arm I (control): Patients receive luteinizing hormone-releasing hormone agonists as per local practice in the absence of unacceptable toxicity.
Arm II (patch): Patients receive 4 transcutaneous estrogen patches, changing twice weekly for 4 weeks. Patients' testosterone levels are measured at week 4. Patients whose testosterone level is > 1.7 nmol/L continue to receive patch as before and have their testosterone level measured every 2 weeks. Patients whose testosterone level is < 1.7 nmol/L at week 4 or any other point receive 3 transcutaneous estrogen patches changed twice weekly in the absence of unacceptable toxicity.
Quality of life is assessed at baseline; at weeks 4, 8, and 12; every 3 months for 24 months.
After completion of study treatment, patients are followed periodically.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 2200 patients will be accrued for this study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anemia, Cardiovascular Complications, Hot Flashes, Osteoporosis, Prostate Cancer
Keywords
hot flashes, anemia, osteoporosis, cardiovascular complications, recurrent prostate cancer, stage III prostate cancer, stage IV prostate cancer, adenocarcinoma of the prostate
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
LHRH agonists
Arm Type
Active Comparator
Arm Description
Patients randomised to the control arm will receive continuous treatment with LHRH agonists as per local practice. Treatment should continue for at least 3 years. LHRH antagonists, such as degarelix, are not allowed on the trial. The recommended "anti-flare" medication is bicalutamide and should be prescribed according to local practice. Control arm medication should be obtained from the hospital pharmacy or GP as per local practice.
Arm Title
Oestrogen Patches
Arm Type
Experimental
Arm Description
Patients randomised to the investigational arm will receive transcutaneous oestrogen patches (100 micrograms/24 hours). Treatment should be planned to continue for at least 3 years. For patients prescribed bicalutamide or flutamide prior to randomisation, this treatment should be discontinued before treatment with the patches can commence (no washout period is needed).
Intervention Type
Drug
Intervention Name(s)
Goserelin
Other Intervention Name(s)
Zoladex
Intervention Description
3.6mg implant, in pre-filled syringe
Intervention Type
Drug
Intervention Name(s)
Estradiol
Other Intervention Name(s)
FemSeven
Intervention Description
Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
Primary Outcome Measure Information:
Title
Progression-Free Survival
Time Frame
Up to 180 months
Title
Overall Survival
Time Frame
Up to 180 months
Secondary Outcome Measure Information:
Title
Hormone activity by castrate levels of hormones
Time Frame
Up to 180 months
Title
Other toxicity
Time Frame
Up to 180 months
Title
Cardiovascular morbidity
Time Frame
Up to 180 months
Title
Cardiovascular mortality
Time Frame
Up to 180 months
Title
Quality of Life
Description
will be measured using patient-completed questionnaires, EORTC QLQ-C30 and PR25 which is prostate specific
Time Frame
Up to 24 months
10. Eligibility
Sex
Male
Maximum Age & Unit of Time
120 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS:
Must meet 1 of the following criteria:
Newly diagnosed patients with any of the following:
Stage T3 or T4, NX, M0 histologically confirmed prostate adenocarcinoma with prostate-specific antigen (PSA) ≥ 20 ng/mL or Gleason score ≥ 6
Any T, N+, M0, or any T, any N, M+ histologically confirmed prostate adenocarcinoma
Multiple sclerotic bone metastases with a PSA ≥ 50 ng/mL without histological confirmation
Patients with histologically confirmed prostate adenocarcinoma previously treated with radical surgery or radiotherapy who are currently in relapse with on of the following:
PSA ≥ 4 ng/mL and rising with doubling time less than 6 months
PSA ≥ 20 ng/mL
Must have written informed consent
Intention to treat with long-term androgen-deprivation therapy
Normal testosterone level prior to hormonal treatment
PATIENT CHARACTERISTICS:
WHO performance status 0-2
No other prior or current malignant disease or cardiovascular system disease that is likely to interfere with study treatment or assessment
No cardiovascular disease, including any of the following:
History of cerebral ischemia (e.g., stroke or transient ischemic attack) within the past 2 years
History of deep vein thrombosis or pulmonary embolism confirmed radiologically
History of myocardial infarction (MI) within the past 6 months OR MI more than 6 months ago with evidence of q-wave anterior infarct on ECG
ECHO or MUGA required for patients with history of ischemic heart disease
Left Ventricular Ejection Fraction ≤ 40%
No condition or situation that could preclude protocol treatment or compliance with follow-up schedule
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
At least 12 months since prior adjuvant or neoadjuvant hormonal therapy for localized prostate cancer AND therapy lasted ≤ 12 months in duration
No prior systemic therapy for locally advanced or metastatic prostate cancer
No concurrent participation in another clinical trial of prostate cancer treatment that would preclude study therapy or outcome measures
Concurrent prophylactic radiotherapy to prevent gynecomastia allowed
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul D. Abel
Organizational Affiliation
Charing Cross Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Queen's Hospital
City
Burton-upon-Trent
State/Province
England
ZIP/Postal Code
DE13 0RB
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-1283-566-333
Facility Name
Addenbrooke's Hospital
City
Cambridge
State/Province
England
ZIP/Postal Code
CB2 2QQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Helen Patterson, MD
Phone
44-122324-5151 ext. 2523 and 2
Facility Name
Walsgrave Hospital
City
Coventry
State/Province
England
ZIP/Postal Code
CV2 2DX
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-24-7660-2020
Facility Name
Mid Cheshire Hospitals Trust- Leighton Hopsital
City
Crewe
State/Province
England
ZIP/Postal Code
CW1 4QJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
J. P. Logue, MD
Phone
44-1270-255-141
Facility Name
Mayday University Hospital
City
Croydon
State/Province
England
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robert A. Huddart, MD
Phone
44-20-8401-3000
Facility Name
Derbyshire Royal Infirmary
City
Derby
State/Province
England
ZIP/Postal Code
DE1 2QY
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-1332-347-141 ext. 2407
Facility Name
Castle Hill Hospital
City
East Yorkshire
State/Province
England
ZIP/Postal Code
HU16 5JQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-1482-875-875
Facility Name
Royal Devon and Exeter Hospital
City
Exeter
State/Province
England
ZIP/Postal Code
EX2 5DW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Denise J. Sheehan, MD
Phone
44-1392-411-611
Facility Name
Grantham and District Hospital
City
Grantham, Lincolnshire
State/Province
England
ZIP/Postal Code
NG31 8DG
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
P. Daruwala
Phone
44-1476-565-232
Facility Name
Ipswich Hospital
City
Ipswich
State/Province
England
ZIP/Postal Code
IP4 5PD
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christopher Scrase, MD
Phone
44-147-370-4177
Facility Name
Kidderminster Hospital
City
Kidderminster Worcestershire
State/Province
England
ZIP/Postal Code
DY11 6RJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-190-576-0635
Facility Name
Leeds Cancer Centre at St. James's University Hospital
City
Leeds
State/Province
England
ZIP/Postal Code
LS9 7TF
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-113-206-6400
Facility Name
St. Mary's Hospital
City
London
State/Province
England
ZIP/Postal Code
W2 1NY
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Simon Stewart, MD
Phone
44-207-886-1132
Email
s.stewart@imperial.ac.uk
Facility Name
Charing Cross Hospital
City
London
State/Province
England
ZIP/Postal Code
W6 8RF
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul D. Abel
Phone
44-20-8383-2268
Facility Name
Maidstone Hospital
City
Maidstone
State/Province
England
ZIP/Postal Code
ME16 9QQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sharon Beesley
Phone
44-1622-729-000
Facility Name
James Cook University Hospital
City
Middlesbrough
State/Province
England
ZIP/Postal Code
TS4 3BW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-1642-850-850
Facility Name
Kings Mill Hospital
City
Nottinghamshire
State/Province
England
ZIP/Postal Code
NG17 4JL
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-162-362-2515
Facility Name
Nottingham City Hospital
City
Nottingham
State/Province
England
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Santhanam Sundar
Phone
44-115-969-1169
Email
santhanam.sundar@nuh.nhs.uk
Facility Name
George Eliot Hospital
City
Nuneaton
State/Province
England
ZIP/Postal Code
CV10 7DJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-024-7635-1351
Facility Name
Alexandra Healthcare NHS
City
Redditch, Worcestershire
State/Province
England
ZIP/Postal Code
B98 7UB
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-015-2750-3030
Facility Name
Hope Hospital
City
Salford
State/Province
England
ZIP/Postal Code
M6 8HD
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Noel Clarke
Phone
44-161-206-5568
Facility Name
Scarborough General Hospital
City
Scarborough
State/Province
England
ZIP/Postal Code
YO12 6QL
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Robertson
Phone
44-1723-368-111
Facility Name
Stepping Hill Hospital
City
Stockport
State/Province
England
ZIP/Postal Code
SK2 7JE
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-161-483-1010
Facility Name
Hillingdon Hospital
City
Uxbridge
State/Province
England
ZIP/Postal Code
UB8 3NN
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alvan J. Pope
Phone
44-1895-238-282
Facility Name
Walsall Manor Hospital
City
Walsall
State/Province
England
ZIP/Postal Code
WS2 9PS
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-1922-721-172
Facility Name
Warwick Hospital
City
Warwick
State/Province
England
ZIP/Postal Code
CV34 5BW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-1926 495-321
Facility Name
Worthing Hospital
City
Worthing
State/Province
England
ZIP/Postal Code
BN11 2DH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ralph Beard
Phone
44-1903-205-111 ext. 5559
Facility Name
Yeovil District Hospital
City
Yeovil
State/Province
England
ZIP/Postal Code
BA21 4AT
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chris Parker
Phone
44-1935-475-122
Facility Name
Ayr Hospital
City
Ayr
State/Province
Scotland
ZIP/Postal Code
KA6 6DX
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-1292-610-555
Facility Name
Beatson West of Scotland Cancer Centre
City
Glasgow
State/Province
Scotland
ZIP/Postal Code
G12 0YN
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Contact Person
Phone
44-141-211-2123
Facility Name
Velindre Cancer Center at Velindre Hospital
City
Cardiff
State/Province
Wales
ZIP/Postal Code
CF14 2TL
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
J. Lester, MD
Phone
44-29-2031-6292
Facility Name
University Hospital of Wales
City
Cardiff
State/Province
Wales
ZIP/Postal Code
CF14 4XW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Howard Kynaston
Phone
44-2920-745-094
12. IPD Sharing Statement
Citations:
PubMed Identifier
29388336
Citation
Gilbert DC, Duong T, Sydes M, Bara A, Clarke N, Abel P, James N, Langley R, Parmar M; STAMPEDE and PATCH Trial Management Groups. Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform. BJU Int. 2018 May;121(5):680-683. doi: 10.1111/bju.14153. Epub 2018 Feb 28. No abstract available.
Results Reference
derived
PubMed Identifier
26707868
Citation
Langley RE, Kynaston HG, Alhasso AA, Duong T, Paez EM, Jovic G, Scrase CD, Robertson A, Cafferty F, Welland A, Carpenter R, Honeyfield L, Abel RL, Stone M, Parmar MK, Abel PD. A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol. Eur Urol. 2016 Jun;69(6):1016-25. doi: 10.1016/j.eururo.2015.11.030. Epub 2015 Dec 17.
Results Reference
derived
PubMed Identifier
23465742
Citation
Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC, Pollock P, Jinks RC, Godsland IF, Kockelbergh R, Clarke NW, Kynaston HG, Parmar MK, Abel PD. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol. 2013 Apr;14(4):306-16. doi: 10.1016/S1470-2045(13)70025-1. Epub 2013 Mar 4.
Results Reference
derived
Links:
URL
http://www.ctu.mrc.ac.uk/our_research/research_areas/cancer/studies/patch_pr09/
Description
Study homepage at the MRC CTU at UCL
Learn more about this trial
Prostate Adenocarcinoma TransCutaneous Hormones
We'll reach out to this number within 24 hrs